Karl Lewis, MD, medical oncologist, associate professor, University of Colorado, discusses sequencing immunotherapy and targeted therapy for patients with melanoma.
Karl Lewis, MD, medical oncologist, associate professor, University of Colorado, discusses sequencing immunotherapy and targeted therapy for patients with melanoma.
The timing of immunotherapy compared to targeted therapy is unknown at this point, Lewis says. It is important for a physician to know the molecular profile of a patient's tumor earlier rather than later in order to know what therapy options there are.
Lewis says there is no clinical data to support if giving immunotherapy therapy is better before or after giving targeted therapy. Most melanoma specialists, Lewis says, will treat a patient with early metastatic disease that is asymptomatic with immunotherapy first so that they have the chance to have a long and durable benefit. However, if the patient does not respond to treatment, targeted therapies can still be used later on.
Brain Cancer Awareness Month: Challenges and Innovations in Treatment
May 13th 2024In an interview with Targeted Oncology for Brain Cancer Awareness Month, Theodore Schwartz, MD, discussed the challenges of targeting brain tumors, emerging therapies, and strategies to overcome the blood-brain barrier.
Read More